UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 671

Sortiert nach

Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement

JAMA : the journal of the American Medical Association, 2018-06, Vol.319 (24), p.2521

2018

Volltextzugriff (PDF)

Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates

The New England journal of medicine, 2020-08, Vol.383 (8), p.743-753

2020

Volltextzugriff (PDF)

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

European journal of cancer (1990), 2012-11, Vol.48 (16), p.3082-3092

2012

Volltextzugriff (PDF)

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

The New England journal of medicine, 2012-11, Vol.367 (18), p.1714-1723

2012

Volltextzugriff (PDF)

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

Annals of oncology, 2012-05, Vol.23 (5), p.1341-1347

2012

Volltextzugriff (PDF)

A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?

Osteoporosis international, 2017-08, Vol.28 (8), p.2465-2473

2017

Volltextzugriff (PDF)

Breast-Cancer Adjuvant Therapy with Zoledronic Acid

The New England journal of medicine, 2011-10, Vol.365 (15), p.1396-1405

2011

Volltextzugriff (PDF)

Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis

Journal of bone and mineral research, 2022-02, Vol.37 (2), p.340-348

2022

Volltextzugriff (PDF)

Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS)

European urology, 2015-03, Vol.67 (3), p.482-491

2015

Volltextzugriff (PDF)

Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review

International journal of oral and maxillofacial surgery, 2015-05, Vol.44 (5), p.568-585

2015

Volltextzugriff (PDF)

Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs

The Journal of the American Dental Association (1939), 2011-11, Vol.142 (11), p.1243

2011

Volltextzugriff (PDF)

Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates

Journal of bone and mineral research, 2008-06, Vol.23 (6), p.826-836

2008

Volltextzugriff (PDF)

Bisphosphonates and risk of cardiovascular events: a meta-analysis

PloS one, 2015-04, Vol.10 (4), p.e0122646-e0122646

2015

Volltextzugriff (PDF)

Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years’ experience in a single center

Osteoporosis international, 2017-11, Vol.28 (11), p.3251-3259

2017

Volltextzugriff (PDF)

Atypical fractures of the femur and bisphosphonate therapy A systematic review of case/case series studies

Bone (New York, N.Y.), 2010-08, Vol.47 (2), p.169-180

2010

Volltextzugriff (PDF)

Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review

Bone (New York, N.Y.), 2014-01, Vol.58, p.126-135

2014

Volltextzugriff (PDF)

The Relationship of Parathyroidectomy and Bisphosphonates With Fracture Risk in Primary Hyperparathyroidism: An Observational Study

Annals of internal medicine, 2016-06, Vol.164 (11), p.715

2016

Volltextzugriff (PDF)

Hypocalcaemia in patients with metastatic bone disease treated with denosumab

European journal of cancer (1990), 2015-09, Vol.51 (13), p.1812-1821

2015

Volltextzugriff (PDF)

Osteoporosis, bisphosphonate use, and risk of moderate or worse hearing loss in women

Journal of the American Geriatrics Society (JAGS), 2021-11, Vol.69 (11), p.3103-3113

2021

Volltextzugriff (PDF)

Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry

Journal of bone and joint surgery. American volume, 2014-11, Vol.96 (22), p.1905

2014

Volltextzugriff (PDF)

Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience

The journal of clinical endocrinology and metabolism, 2015-11, Vol.100 (11), p.4163-4171

2015

Volltextzugriff (PDF)

Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density

The journal of clinical endocrinology and metabolism, 2020-10, Vol.105 (10), p.3215-3225

2020

Volltextzugriff (PDF)

Bisphosphonates and the risk of atypical femur fractures

Bone (New York, N.Y.), 2022-03, Vol.156, p.116297-116297, Article 116297

2022

Volltextzugriff (PDF)

Risk Factors for Osteonecrosis of the Jaws: a Case-Control Study from the CONDOR Dental PBRN

Journal of dental research, 2011-04, Vol.90 (4), p.439-444

2011

Volltextzugriff (PDF)

1 – 25 von 671

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Oral And Maxillofacial Surgery

SpracheJapanisch

ThemaRisk Factors

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(603)
Mit Volltextzugriff
(497)

Publikationsform

Artikel
(670)
magazinearticle
(1)

Sprache

9 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(668)
Science & Technology
(525)
Life Sciences & Biomedicine
(512)
Diphosphonates - Adverse Effects
(488)
Female
(390)
Bone Density Conservation Agents - Adverse Effects
(372)
Diphosphonates - Therapeutic Use
(336)
Aged
(272)
Male
(271)
Middle Aged
(240)
Osteoporosis
(235)
Bone Density Conservation Agents - Therapeutic Use
(208)
Bisphosphonates
(207)
Osteoporosis - Drug Therapy
(190)
Diphosphonates - Administration & Dosage
(170)
Osteonecrosis - Chemically Induced
(152)
Aged, 80 And Over
(139)
Bone Density Conservation Agents - Administration & Dosage
(124)
Biological And Medical Sciences
(117)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement

Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?

Breast-Cancer Adjuvant Therapy with Zoledronic Acid

Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis

Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS)

Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials

Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review

Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs

Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates

Bisphosphonates and risk of cardiovascular events: a meta-analysis

Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years’ experience in a single center

Atypical fractures of the femur and bisphosphonate therapy A systematic review of case/case series studies

Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review

The Relationship of Parathyroidectomy and Bisphosphonates With Fracture Risk in Primary Hyperparathyroidism: An Observational Study

Hypocalcaemia in patients with metastatic bone disease treated with denosumab

Osteoporosis, bisphosphonate use, and risk of moderate or worse hearing loss in women

Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry

Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience

Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density

Bisphosphonates and the risk of atypical femur fractures

Risk Factors for Osteonecrosis of the Jaws: a Case-Control Study from the CONDOR Dental PBRN

Aktive Filter

Suchergebnisse filtern